University of Illinois
Chicago IL
MD - Medicine
1971
University of Wisconsin
Madison WI
BS - Liberal Arts
1967
Oligometastasis: Past, Present, Future.
Gutiontov SI, Pitroda SP, Weichselbaum RR. Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020 Nov 01; 108(3):530-538.
PMID: 32976785
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
Prasanna PG, Woloschak GE, DiCarlo AL, Buchsbaum JC, Schaue D, Chakravarti A, Cucinotta FA, Formenti SC, Guha C, Hu DJ, Khan MK, Kirsch DG, Krishnan S, Leitner WW, Marples B, McBride W, Mehta MP, Rafii S, Sharon E, Sullivan JM, Weichselbaum RR, Ahmed MM, Vikram B, Coleman CN, Held KD. Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks? Radiat Res. 2020 Oct 12.
PMID: 33045077
Improved survival associated with local tumor response following multi-site radiotherapy and pembrolizumab: secondary analysis of a phase I trial.
Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez CA, Janisch LA, Hseu R, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved survival associated with local tumor response following multi-site radiotherapy and pembrolizumab: secondary analysis of a phase I trial. Clin Cancer Res. 2020 Oct 07.
PMID: 33028595
p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability.
Wu L, Crawley CD, Garofalo A, Nichols JW, Campbell PA, Khramtsova GF, Olopade OI, Weichselbaum RR, Yamini B. p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. Nat Commun. 2020 10 06; 11(1):5007.
PMID: 33024116
Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination.
Ni K, Lan G, Guo N, Culbert A, Luo T, Wu T, Weichselbaum RR, Lin W. Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination. Sci Adv. 2020 Oct; 6(40).
PMID: 33008911
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.
Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin TY, Pan CX, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, Monjazeb AM, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun. 2020 09 14; 11(1):4591.
PMID: 32929084
Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy.
Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 Sep 01; 108(1):17-26.
PMID: 32819613
4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis.
Bryan DS, Stack M, Krysztofiak K, Cichon U, Thomas DG, Surcel A, Schiffhauer ES, Beckett MA, Khodarev NN, Xue L, Poli EC, Pearson AT, Posner MC, Robinson DN, Rock RS, Weichselbaum RR. 4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis. Proc Natl Acad Sci U S A. 2020 09 08; 117(36):22423-22429.
PMID: 32848073
Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.
Liauw SL, Ham SA, Das LC, Rudra S, Packiam VT, Koshy M, Weichselbaum RR, Becker YT, Bodzin AS, Eggener SE. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 Aug 01; 112(8):847-854.
PMID: 31728517
Is It Worth It? Consequences of Definitive Head and Neck Reirradiation.
Foster CC, Fan M, Lee NY, Yom SS, Heaton CM, Deraniyagala R, Amdur R, Weichselbaum RR, Haraf DJ. Is It Worth It? Consequences of Definitive Head and Neck Reirradiation. Semin Radiat Oncol. 2020 Jul; 30(3):212-217.
PMID: 32503785